Colchicine Use Is Associated with Decreased Prevalence of Myocardial Infarction in Patients with Gout

Abstract

Objective The ability of antiinflammatory strategies to alter cardiovascular risk has not been rigorously examined. Colchicine is an antiinflammatory agent that affects macrophages, neutrophils, and endothelial cells, all of which are implicated in the pathogenesis of cardiovascular disease. We examined whether colchicine use was associated with a reduced risk of myocardial infarction (MI) in patients with gout. Methods We conducted a retrospective, cross-sectional study of all patients with an International Classification of Diseases, 9th ed, code for gout in the electronic medical record (EMR) of the New York Harbor Healthcare System Veterans Affairs network and ≥ 1 hospital visit between August 2007 and August 2008. Hospital pharmacy data were used to identify patients who had filled at least 1 colchicine prescription versus those who had not. Demographics and CV comorbidities were collected by EMR review. The primary outcome was diagnosis of MI. Secondary outcomes included all-cause mortality and C-reactive protein (CRP) level. Results In total, 1288 gout patients were identified. Colchicine (n = 576) and no colchicine (n = 712) groups had similar baseline demographics and serum urate levels. Prevalence of MI was 1.2% in the colchicine versus 2.6% in the no-colchicine group (p = 0.03). Colchicine users also had fewer deaths and lower CRP levels, although these did not achieve statistical significance. Colchicine effects persisted when allopurinol users were excluded from the analysis. Conclusion In this hypothesis-generating study, gout patients who took colchicine had a significantly lower prevalence of MI and exhibited trends toward reduced all-cause mortality and lower CRP level versus those who did not take colchicine.

Colchicine Improves Survival, Left Ventricular Remodeling, and Chronic Cardiac Function After Acute Myocardial Infarction

“…5, 6 Several studies reported that colchicine users had a lower prevalence of MI in patients with gout. 7,8 Recent studies have demonstrated that nucleotide-binding oligomerization domain-like receptors, pyrin domaincontaining 3 (NLRP3) inflammasome, is associated with Effects of Colchicine on Myocardial Infarction of Health, Bethesda, MD, USA).…”

Anti-Inflammatory Therapy for Atherosclerosis: Contribution to and Lessons of Rheumatology

“…Получены данные об уменьшении риска кардиова-скулярных катастроф у пациентов с хронической подагрой на фоне терапии колхицином, ассоциирующейся со сни-жением концентрации СРБ [45]. Следует напомнить, что не только кристаллы ХС, но и кристаллы моноурата на-трия (МУН), образование которых является ключевым ме-ханизмом патогенеза подагрического артрита, и даже рас-творимая мочевая кислота в высокой концентрации вызы-вает активацию NLRP3-инфламмасомы, приводящую к синтезу ИЛ1β [46].…”

Hyperurikämie – mehr als Gicht

“…Eine harn säuresenkende Therapie hat somit sowohl Einfluss auf die klassische Gicht als auch auf die Gefäßfunktion in diversen Gefäß provinzen. Die Gichttherapie mit Colchi cin reduziert das Herzinfarktrisiko [8]. Im retrospektiven Vergleich zwischen Al lopurinol und Colchicin schützte die Allo purinoltherapie signifikant vor dem Auf treten eines Myokardinfarkts [13].…”